[Entry inhibitors. Ring-free for a new principle of action]
1KIS-Kuratorium für Immunschwäche, München.
Abstract:
Entry-inhibitors represent a new option in antiretroviral therapy. They prevent infection of HIV target-cells. According to their mechanism of action they can be divided into three groups: attachment-inhibitors, corezeptor-antagonists and fusion-inhibitors. The fusion-inhibitor T-20 (Enfuvirtide) will be the first substance to be licensed in 2003. It has been shown that entry-inhibition is a realistic goal for clinical use. Until now T-20 was mainly added to an optimized background regimen in intensively pretreated patients. To achieve the best efficacy a combination of substances with only slight preexisting resistance seems to be favorable. Further efforts in providing orally applicable drugs with little potential for developing resistance and with synergistic effects are required.
Related Concept Videos
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Enzyme Inhibition
Anthelminthic Agents
Inhibitors Of Virion Release
Inhibitors of Bacterial DNA Synthesis

